Thermo Fisher Scientific (TMO) : Central Bank Trust Co reduced its stake in Thermo Fisher Scientific by 19.74% during the most recent quarter end. The investment management company now holds a total of 187 shares of Thermo Fisher Scientific which is valued at $29,585 after selling 46 shares in Thermo Fisher Scientific , the firm said in a disclosure report filed with the SEC on Oct 7, 2016.Thermo Fisher Scientific makes up approximately 0.01% of Central Bank Trust Co’s portfolio.
Other Hedge Funds, Including , Sadoff Investment Management reduced its stake in TMO by selling 600 shares or 13.48% in the most recent quarter. The Hedge Fund company now holds 3,850 shares of TMO which is valued at $609,109. Thermo Fisher Scientific makes up approx 0.07% of Sadoff Investment Management’s portfolio.Eqis Capital Management reduced its stake in TMO by selling 955 shares or 7.23% in the most recent quarter. The Hedge Fund company now holds 12,261 shares of TMO which is valued at $1,940,671. Thermo Fisher Scientific makes up approx 0.12% of Eqis Capital Management’s portfolio.Washington Trust Bank boosted its stake in TMO in the latest quarter, The investment management firm added 32 additional shares and now holds a total of 2,243 shares of Thermo Fisher Scientific which is valued at $355,022. Thermo Fisher Scientific makes up approx 0.09% of Washington Trust Bank’s portfolio.Cullinan Associates Inc boosted its stake in TMO in the latest quarter, The investment management firm added 3,270 additional shares and now holds a total of 21,780 shares of Thermo Fisher Scientific which is valued at $3,447,338. Thermo Fisher Scientific makes up approx 0.30% of Cullinan Associates Inc’s portfolio.
Thermo Fisher Scientific closed down -0.23 points or -0.15% at $158.21 with 10,87,001 shares getting traded on Friday. Post opening the session at $159, the shares hit an intraday low of $157 and an intraday high of $159 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, Thermo Fisher Scientific reported $2.03 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $2.01. The company had revenue of $4535.20 million for the quarter, compared to analysts expectations of $4493.28 million. The company’s revenue was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.84 EPS.
Many Wall Street Analysts have commented on Thermo Fisher Scientific. JP Morgan Resumed Thermo Fisher Scientific on Sep 22, 2016 to “Overweight”, Price Target of the shares are set at $180.Thermo Fisher Scientific was Downgraded by Cleveland Research to ” Neutral” on Sep 9, 2016.
Thermo Fisher Scientific Inc. is a provider of analytical instruments equipment reagents and consumables software and services for research manufacturing analysis discovery and diagnostics. The company operates through four segments: Life Sciences Solutions provides reagents instruments and consumables used in biological and medical research discovery and production of new drugs and vaccines as well as diagnosis of disease; Analytical Instruments provides instruments consumables software and services that are used in the laboratory; Specialty Diagnostics offers diagnostic test kits reagents culture media instruments and associated products and Laboratory Products and Services offers self-manufactured and sourced products for the laboratory.